 |
|
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yu-Xiao Yang, MD, MSCE;
James D. Lewis, MD, MSCE;
Solomon Epstein, MD;
David C. Metz, MD
JAMA. 2006;296:2947-2953.
Context Proton pump inhibitors (PPIs) may interfere with calcium absorption through induction of hypochlorhydria but they also may reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps.
Objective To determine the association between PPI therapy and risk of hip fracture.
Design, Setting, and Patients A nested case-control study was conducted using the General Practice Research Database (1987-2003), which contains information on patients in the United Kingdom. The study cohort consisted of users of PPI therapy and nonusers of acid suppression drugs who were older than 50 years. Cases included all patients with an incident hip fracture. Controls were selected using incidence density sampling, matched for sex, index date, year of birth, and both calendar period and duration of up-to-standard follow-up before the index date. For comparison purposes, a similar nested case-control analysis for histamine 2 receptor antagonists was performed.
Main Outcome Measure The risk of hip fractures associated with PPI use.
Results There were 13 556 hip fracture cases and 135 386 controls. The adjusted odds ratio (AOR) for hip fracture associated with more than 1 year of PPI therapy was 1.44 (95% confidence interval [CI], 1.30-1.59). The risk of hip fracture was significantly increased among patients prescribed long-term high-dose PPIs (AOR, 2.65; 95% CI, 1.80-3.90; P<.001). The strength of the association increased with increasing duration of PPI therapy (AOR for 1 year, 1.22 [95% CI, 1.15-1.30]; 2 years, 1.41 [95% CI, 1.28-1.56]; 3 years, 1.54 [95% CI, 1.37-1.73]; and 4 years, 1.59 [95% CI, 1.39-1.80]; P<.001 for all comparisons).
Conclusion Long-term PPI therapy, particularly at high doses, is associated with an increased risk of hip fracture.
Author Affiliations: Division of Gastroenterology (Drs Yang, Lewis, and Metz), Center for Clinical Epidemiology and Biostatistics (Drs Yang and Lewis), Department of Biostatistics and Epidemiology (Drs Yang and Lewis), and Division of Endocrinology (Dr Epstein), University of Pennsylvania School of Medicine, Philadelphia; and Department of Medicine, Doylestown Hospital Research Center, Doylestown, Pa (Dr Epstein).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Proton Pump Inhibitor Therapy and Hip Fracture Risk
Jordan L. Geller and John S. Adams
JAMA. 2007;297(13):1429.
EXTRACT
| FULL TEXT
Proton Pump Inhibitor Therapy and Hip Fracture Risk—Reply
Yu-Xiao Yang, James D. Lewis, Solomon Epstein, and David C. Metz
JAMA. 2007;297(13):1429-1430.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis
Latimer et al.
BMJ 2009;339:b2538-b2538.
ABSTRACT
| FULL TEXT
Treatment of chronic gastro-oesophageal reflux disease
Ford and Moayyedi
BMJ 2009;339:b2481-b2481.
FULL TEXT
Radiofrequency Energy Delivery to the Lower Esophageal Sphincter (Stretta Procedure) Does Not Provide Long-term Symptom Control
Dundon et al.
SURG INNOV 2008;15:297-301.
ABSTRACT
Gastroesophageal Reflux Disease
Kahrilas
NEJM 2008;359:1700-1707.
FULL TEXT
Proton pump inhibitors: balancing the benefits and potential fracture risks
Richards and Goltzman
CMAJ 2008;179:306-307.
FULL TEXT
Use of proton pump inhibitors and risk of osteoporosis-related fractures
Targownik et al.
CMAJ 2008;179:319-326.
ABSTRACT
| FULL TEXT
Cost-effectiveness of Proton Pump Inhibitor Cotherapy in Patients Taking Long-term, Low-Dose Aspirin for Secondary Cardiovascular Prevention
Saini et al.
Arch Intern Med 2008;168:1684-1690.
ABSTRACT
| FULL TEXT
Overprescription of Antireflux Medications for Infants With Regurgitation: In Reply
Khoshoo and Edell
Pediatrics 2008;121:1070-1071.
FULL TEXT
A 32-Year-Old Woman With Chronic Abdominal Pain
Lacy and Cash
JAMA 2008;299:555-565.
ABSTRACT
| FULL TEXT
Overprescribing proton pump inhibitors
Forgacs and Loganayagam
BMJ 2008;336:2-3.
FULL TEXT
What's New in Orthopaedic Trauma
Cole et al.
JBJS 2007;89:2560-2577.
FULL TEXT
Bone Health and Osteoporosis: The Role of Vitamin K and Potential Antagonism by Anticoagulants
Pearson
Nutr Clin Pract 2007;22:517-544.
ABSTRACT
| FULL TEXT
Letter by Wallis and Penckofer Regarding Article, "Calcium/Vitamin D Supplementation and Cardiovascular Events"
Wallis and Penckofer
Circulation 2007;116:e86-e86.
FULL TEXT
Patient Assessment in the Diagnosis, Prevention, and Treatment of Osteoporosis
Lata and Elliott
Nutr Clin Pract 2007;22:261-275.
ABSTRACT
| FULL TEXT
JournalScan
Gut 2007;56:715-715.
FULL TEXT
Proton Pump Inhibitor Therapy and Hip Fracture Risk
Geller and Adams
JAMA 2007;297:1429-1429.
FULL TEXT
PPIs and Risk for Hip Fracture
JWatch General 2007;2007:2-2.
FULL TEXT
Do PPIs Increase Risk for Hip Fracture?
JWatch Gastroenterology 2007;2007:1-1.
FULL TEXT
|
